Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innovent Biologics ( (HK:1801) ) has shared an announcement.
Innovent Biologics reported a sharp rise in 2025 revenue to RMB13.04 billion, a 38.4% year-on-year increase that set a new scale benchmark in China’s biopharmaceutical sector. The performance was underpinned by its dual-engine portfolio strategy and the strong ramp-up of cardiovascular and metabolism products, highlighting the growing importance of these assets in its product mix.
The company achieved its first full year of profitability, posting IFRS net profit of RMB813.6 million and a jump in non-IFRS profit and EBITDA, driven by economies of scale and operating efficiency gains. Management positioned this profitability inflection as a foundation for the next phase of growth, signaling stronger financial resilience and a bid to elevate Innovent into the ranks of global premier biopharmaceutical players.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$115.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a China-based biopharmaceutical company focused on developing and commercializing innovative medicines. The group operates in therapeutic areas including oncology and cardiovascular and metabolism, leveraging a broad portfolio and a commercial team aimed at rapidly scaling revenue in the domestic market and expanding its global presence.
Average Trading Volume: 11,049,180
Technical Sentiment Signal: Buy
Current Market Cap: HK$143.2B
For a thorough assessment of 1801 stock, go to TipRanks’ Stock Analysis page.